FEMASYS INC - 8-K Filing
Femasys Inc. reported Q1 2026 financial results with revenue of $424,889 (up 24.5% YoY) and net income of $846,100 ($0.00 EPS), compared to a prior-year loss of $5.9 million (-$0.23 EPS). The company also announced key corporate updates including the launch of FemaSeed Complete at ACOG 2026, strategic partnerships in Israel and Switzerland, executive appointments, and progress on clinical trials for FemBloc. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $FEMY